115 related articles for article (PubMed ID: 21347786)
1. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Vallböhmer D; Alakus H; Kütting F; Lurje G; Bollschweiler E; Wienand-Dorweiler A; Drebber U; Hölscher AH; Metzger R
J Gastrointest Surg; 2009 Aug; 13(8):1411-21. PubMed ID: 19421825
[TBL] [Abstract][Full Text] [Related]
5. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
[TBL] [Abstract][Full Text] [Related]
6. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Thomas F; Motsinger-Reif AA; Hoskins JM; Dvorak A; Roy S; Alyasiri A; Myerson RJ; Fleshman JW; Tan BR; McLeod HL
Br J Cancer; 2011 Nov; 105(11):1654-62. PubMed ID: 22045187
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer.
Lin VC; Lu TL; Yin HL; Yang SF; Lee YC; Liu CC; Huang CY; Yu CC; Chang TY; Huang SP; Bao BY
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916838
[TBL] [Abstract][Full Text] [Related]
9. An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
Li X; Cai H; Zheng W; Tong M; Li H; Ao L; Li J; Hong G; Li M; Guan Q; Yang S; Yang D; Lin X; Guo Z
Oncotarget; 2016 Feb; 7(8):8743-55. PubMed ID: 26840027
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
11. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.
Boonstra JJ; van Marion R; Tilanus HW; Dinjens WN
J Gastrointest Surg; 2011 Jan; 15(1):48-56. PubMed ID: 20922573
[TBL] [Abstract][Full Text] [Related]
12. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim A; Ylstra B; van Essen HF; Benner C; Stenning S; Langley R; Allum W; Cunningham D; Inam I; Hewitt LC; West NP; Meijer GA; van de Wiel MA; Grabsch HI
Oncotarget; 2016 Jul; 7(28):44084-44095. PubMed ID: 27286451
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer.
Bachmann K; Shahmiri S; Kaifi J; Schurr P; Mann O; Rawnaq T; Block S; Kalinin V; Izbicki JR; Strate T
J Gastrointest Surg; 2009 Feb; 13(2):181-7. PubMed ID: 19052822
[TBL] [Abstract][Full Text] [Related]
14. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP; Carter R; Gillies RS; Findlay JM; Kartsonaki C; Castro-Giner F; Sahgal N; Wang LM; Chetty R; Maynard ND; Cazier JB; Buffa F; McHugh PJ; Tomlinson I; Middleton MR; Sharma RA
Sci Rep; 2018 May; 8(1):7265. PubMed ID: 29739952
[TBL] [Abstract][Full Text] [Related]
15. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.
Findlay JM; Castro-Giner F; Makino S; Rayner E; Kartsonaki C; Cross W; Kovac M; Ulahannan D; Palles C; Gillies RS; MacGregor TP; Church D; Maynard ND; Buffa F; Cazier JB; Graham TA; Wang LM; Sharma RA; Middleton M; Tomlinson I
Nat Commun; 2016 Apr; 7():11111. PubMed ID: 27045317
[TBL] [Abstract][Full Text] [Related]
16. Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.
Sun C; Niu P; Zhang X; Zhao L; Wang W; Luan X; Han X; Chen Y; Zhao D
BMC Cancer; 2023 Oct; 23(1):996. PubMed ID: 37853387
[TBL] [Abstract][Full Text] [Related]
17. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Murugaesu N; Wilson GA; Birkbak NJ; Watkins T; McGranahan N; Kumar S; Abbassi-Ghadi N; Salm M; Mitter R; Horswell S; Rowan A; Phillimore B; Biggs J; Begum S; Matthews N; Hochhauser D; Hanna GB; Swanton C
Cancer Discov; 2015 Aug; 5(8):821-831. PubMed ID: 26003801
[TBL] [Abstract][Full Text] [Related]
18. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Li D; Liu H; Jiao L; Chang DZ; Beinart G; Wolff RA; Evans DB; Hassan MM; Abbruzzese JL
Cancer Res; 2006 Mar; 66(6):3323-30. PubMed ID: 16540687
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.
Noorani A; Bornschein J; Lynch AG; Secrier M; Achilleos A; Eldridge M; Bower L; Weaver JMJ; Crawte J; Ong CA; Shannon N; MacRae S; Grehan N; Nutzinger B; O'Donovan M; Hardwick R; Tavaré S; Fitzgerald RC;
Genome Res; 2017 Jun; 27(6):902-912. PubMed ID: 28465312
[TBL] [Abstract][Full Text] [Related]
20. Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome.
Hartmann D; von Figura G; Song Z; Harden S; Scott LC; Evans TR; Rudolph KL; Bilsland AE; Keith WN
Future Oncol; 2015; 11(2):193-203. PubMed ID: 25040106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
